

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Multiple Myeloma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following progression-free survival outcomes was reported in the Phase III ENDURANCE (ECOG-E1A11) trial evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (RVd) as initial therapy for patients with newly diagnosed multiple myeloma (MM)?
  - a. KRd was inferior to RVd
  - b. KRd was noninferior/equivalent to RVd
  - c. KRd was superior to RVd
2. What was observed in the Phase II DREAMM-6 study evaluating the anti-B-cell maturation antigen (anti-BCMA) antibody-drug conjugate belantamab mafodotin in combination with bortezomib/dexamethasone for patients with relapsed/refractory MM?
  - a. Unacceptably high rates of Grade 5 adverse events
  - b. A low overall response rate (<10%)
  - c. Frequent ocular toxicities
3. What is the target of the CAR (chimeric antigen receptor) T-cell therapy idecabtagene vicleucel evaluated in the pivotal Phase II KarMMa study for patients with MM?
  - a. CD19
  - b. BCMA
  - c. CD20
4. Which of the following drug types best describes the mechanism of action of the novel agent CC-92480?
  - a. Anti-CD38 antibody
  - b. Bcl-2-targeted agent
  - c. BCMA-targeted agent
  - d. CELMoD (cereblon E3 ligase modulator)